Physician profile
James Odor
NPI 1659317246
$2,161,080.17
in general payments reported to CMS, 2019-2025
16 companies · $88.81 in 2025
The $88.81 reported for 2025 was less than what a typical provider received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $302 · 2020: $197 · 2021: $720K · 2022: $720K · 2023: $720K · 2024: $56.71 · 2025: $88.81.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Acquisitions: $720K · Food and Beverage: $218.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Acquisitions | $720,000.00 |
| Food and Beverage | $218.02 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Omnia Medical, LLC | $2,160,000.00 | 2021-2023 | |
| Stryker Corporation | $326.69 | 2020-2021 | |
| Horizon Therapeutics Plc | $163.03 | 2019-2021 | |
| Smith+Nephew, INC. | $125.52 | 2022-2023 | Evos |
| Aesculap Implant Systems, LLC | $117.61 | 2019 | |
| Radius Health, INC. | $91.94 | 2020-2025 | Tymlos |
| Depuy Synthes Sales INC. | $66.07 | 2025 | Symphony |
| Amgen INC. | $30.54 | 2021-2023 | Prolia, Evenity |
| Takeda Pharmaceuticals U.S.A., INC. | $29.59 | 2019 | |
| Integra Lifesciences Corporation | $25.81 | 2022 | |
| Baxter Healthcare | $20.83 | 2023 | Floseal |
| Si-Bone, INC. | $19.49 | 2024 | |
| Arbor Pharmaceuticals, INC. | $17.60 | 2022 | |
| Astrazeneca Pharmaceuticals Lp | $16.67 | 2019 | |
| Medtronic, INC. | $14.48 | 2024 | Stealth Autoguide System |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Vertiflex, INC. | $14.30 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Odor listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.